Stoke Therapeutics completes dosing in first two cohorts of Phase 1 OSPREY trial for STK-002 in optic atrophy
Bitget2026/10/06 12:06Stoke Therapeutics flagged new Phase 1 progress for STK-002, an RNA-based therapy aimed at autosomal dominant optic atrophy. Preclinical findings and early clinical updates will be presented at the American Academy of Ophthalmology meeting on Oct. 9-12, 2026. Dosing has finished in the first two cohorts of the OSPREY study, with the third cohort expected to complete by year-end 2026. Initial safety and efficacy readouts are expected in H1 2027, a key marker for next-stage development decisions. The program targets the disease’s genetic driver by seeking to raise OPA1 protein levels, with the goal of improving vision. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Stoke Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202610060800BIZWIRE_USPR_____20261001_BW196435) on October 06, 2026, and is solely responsible for the information contained therein.
- Stoke Therapeutics flagged new Phase 1 progress for STK-002, an RNA-based therapy aimed at autosomal dominant optic atrophy.
- Preclinical findings and early clinical updates will be presented at the American Academy of Ophthalmology meeting on Oct. 9-12, 2026.
- Dosing has finished in the first two cohorts of the OSPREY study, with the third cohort expected to complete by year-end 2026.
- Initial safety and efficacy readouts are expected in H1 2027, a key marker for next-stage development decisions.
- The program targets the disease’s genetic driver by seeking to raise OPA1 protein levels, with the goal of improving vision.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
U.S. House May Subpoena NVIDIA CEO Jensen Huang
Prothena 10% Owner William P. Scully Acquires $1.19 Million in Common Shares
Brian Armstrong: Assets deposited in the Base lending market reach 7.49 billions USD
The 10 AI Altcoins Developers Are Focusing On the Most Have Been Revealed
Crypto prices
More
